China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
Policy / Regulatory

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection
CompanyDeals

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION
CompanyDrug

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION

Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency
CompanyDeals

Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC
CompanyDrug

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform
CompanyDeals

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform

European Commission Approves AbbVie's RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor
CompanyDrug

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly's Foundayo
Company

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly’s Foundayo

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers
CompanyDrug

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline
Company

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline

Jenscare's JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market
CompanyMedical Device

Jenscare’s JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market

Roche Reports Positive Phase II Topline Data for Enicepatide – Once‑Weekly GLP‑1/GIP Agonist Cuts HbA1c by 2.65% and Body Weight by 15.5% at 48 Weeks
CompanyDrug

Roche Reports Positive Phase II Topline Data for Enicepatide – Once‑Weekly GLP‑1/GIP Agonist Cuts HbA1c by 2.65% and Body Weight by 15.5% at 48 Weeks